Dopo l'orario di chiusura: 19.18 0.22 +1.16%

Pharvaris NV (PHVS)

Pharvaris NV Borsa (PHVS) Ultime notizie

Pharvaris NV (PHVS)

Pharvaris NV Borsa (PHVS) Ultime notizie

When the Price of (PHVS) Talks, People Listen - Stock Traders Daily

Morgan Stanley Reiterates Pharvaris (PHVS) Equal-Weight Recommendation - MSN

Objective long/short (PHVS) Report - Stock Traders Daily

Pharvaris (NASDAQ:PHVS) Price Target Lowered to $31.00 at Wedbush - Defense World

Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses - WDRB

Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses

Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses - WDRB

Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update - br.ADVFN.com

Pharvaris Advances HAE Treatment in Solid Q1 2024 - TipRanks.com - TipRanks

Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update

Pharvaris Excels in HAE Treatment Advances - TipRanks.com - TipRanks

Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer

Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - Investing.com India

PHVS Stock Quote Price and Forecast - CNN

Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference

Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses

Private equity firms who have a significant stake must be disappointed along with institutions after Pharvaris N.V.'s (NASDAQ:PHVS) market cap dropped by US$168m - Simply Wall St

Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses

Pharvaris to Participate in the Leerink Global Biopharma Conference 2024

Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting

Pharvaris Announces Extraordinary Meeting of Shareholders

Pharvaris to Present at the WSAAI Annual Meeting 2024

Ionis' (IONS) Donidalorsen Meets Late-Stage HAE Study Goal

Pharvaris (PHVS) Up as FDA Lifts Clinical Hold on HAE Program - Yahoo Finance

Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks

Pharvaris Stock: Digging Deep For Sufficient Market Size (NASDAQ:PHVS) - Seeking Alpha

Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities

Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023

Pharvaris (PHVS) Stock Up 18% on HAE Drug Meeting Study Goal

Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study Data

Analyst Expectations for Pharvaris's Future

Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study Data - Yahoo Finance

Gold Moves Higher; Campbell Soup Earnings Top Expectations

Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Crude Oil Down 4%; Pharvaris Shares Spike Higher

THOR Industries Reports Upbeat Earnings, Joins Dave & Buster's Entertainment, Campbell Soup And Other Big Stocks Moving Higher On Wednesday

US Stocks Higher; Private Payrolls Rise By 103,000 In November

Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded Warrants

Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks

Crude Oil Down 4%; Pharvaris Shares Spike Higher - Markets Insider

FDA Removes Clinical Hold Of Pharvaris' Deucrictibant For On-Demand Treatment Of HAE - Yahoo Finance

Pharvaris to embark on 6-month tox test in hopes of reversing US clinical hold for HAE asset - Fierce Biotech

Pharvaris NV (NASDAQ: PHVS) could surge more than 20% from current levels - BP Journal

Pharvaris Shares Surges On Positive Data From HAE Attacks Study, Makes Way For FDA To Remove Clinical Hold - Yahoo Finance

Kalvista's [in]Komplete study gives boost to Orladeyo blockbuster ambitions - BioWorld Online

Siegall resigns as Umoja chair - BioCentury

Pharvaris BV raises $66m to advance oral HAE drug - European Biotechnology News

Simile a PHVS